Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
AssigneePaion Deutschland GmbH
InventorsMariola Sohngen, Wolfgang Sohngen, Dirk Eyding, Yasir Shafeek Al-Rawi
Life of this patent
Estimating the term…
Abstract
The invention refers to the use of non-neurotoxic plasminogen activating factors, e.g., from Desmodus rotundus (DSPA) or genetically modified plasminogen activating factors, for example of human origin, for the therapeutic treatment of stroke in mammals.
Claims16
A method of treating stroke in a mammal, comprising administering to the mammal a composition comprising DSPAα1 in an amount from 60 to 230 μg/kg body weight of the mammal.
A method for producing a non-neurotoxic plasminogen activating factor comprising at least one of the following steps for the modification of the plasminogen activating factor:
- introducing at least a part of a cymogenic triade into the plasminogen activating factor;
- substituting Asp194 or a homologous aspartate in the plasminogen activating factor;
- substituting the hydrophobic amino acid residues in the autolysis loop or in homologous peptide sections of the plasminogen activating factor;
- or
- introducing a mutation in the cymogene for preventing the catalysis of the cymogene by plasmin.
Dependencies are inferred from the claim text.